Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity

Suschak, John; Williams, James A.; Schmaljohn, Connie S.

doi:10.1080/21645515.2017.1330236

Cited by 201 publications

(191 citation statements)

References 173 publications

(173 reference statements)

Supporting

Mentioning

188

Contrasting

Unclassified

Order By: Relevance

“…However, these early promising results did not lead to substantial investment in developing mRNA therapeutics, largely owing to concerns associated with mRNA instability, high innate immunogenicity and inefficient in vivo delivery. Instead, the field pursued DNA-based and protein-based therapeutic approaches 7,8 .…”

mentioning

confidence: 99%

mRNA vaccines — a new era in vaccinology

Pardi

Hogan

Porter

et al. 2018

Nat Rev Drug Discov

3,275

3,330

View full text Add to dashboard Cite

mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. However, their application has until recently been restricted by the instability and inefficient in vivo delivery of mRNA. Recent technological advances have now largely overcome these issues, and multiple mRNA vaccine platforms against infectious diseases and several types of cancer have demonstrated encouraging results in both animal models and humans. This Review provides a detailed overview of mRNA vaccines and considers future directions and challenges in advancing this promising vaccine platform to widespread therapeutic use.

show abstract

mentioning

confidence: 99%

mRNA vaccines — a new era in vaccinology

Pardi

Hogan

Porter

et al. 2018

Nat Rev Drug Discov

3,275

3,330

View full text Add to dashboard Cite

show abstract

“…Recently, intradermal immunization of pigs with a DNA vaccine expressing GRA1-GRA7 of Toxoplasma antigens elicited high humoral and cellular immunity. The study proved that DNA vaccine could be effectively induce strong immune protection [37]. In addition, the potential of the tachyzoites of strain S48 in reducing the number of cysts in pork, and thus, improving food safety has been highlighted [38].…”

Section: Vaccine In Cats and Livestockmentioning

confidence: 96%

Epitope-based vaccine as a universal vaccination strategy against Toxoplasma gondii infection: A mini-review

et al. 2019

View full text Add to dashboard Cite

Despite the significant progress in the recent efforts toward developing an effective vaccine against toxoplasmosis, the search for new protective vaccination strategy still remains a challenge and elusive goal because it becomes the appropriate way to prevent the disease. Various experimental approaches in the past few years showed that developing a potential vaccine against the disease can be achievable. The combination of multi-epitopes expressing different stages of the parasite life cycle has become an optimal strategy for acquiring a potent, safe, and effective vaccine. Epitope-based vaccines have gained attention as alternative vaccine candidates due to their ability of inducing protective immune responses. This mini-review highlights the current status and the prospects of Toxoplasma gondii vaccine development along with the application of epitope-based vaccine in the future parasite immunization as a novel under development and evaluation strategy.

show abstract

“…Co‐administration of antigenic DNA vaccine plasmid with molecular adjuvant plasmids expressing cytokines, chemokines, or co‐stimulatory molecules can also be efficient as it may stimulate both local antigen presenting cells and cells in the draining lymph node. The results from these approaches have shown promise in animal models …”

Section: Vp6 Immunogensmentioning

confidence: 99%

Rotavirus VP6 as a potential vaccine candidate

Afchangi

Jalilvand

Mohajel

et al. 2019

Reviews in Medical Virology

View full text Add to dashboard Cite

Summary By the age of 5 years, virtually all children have been infected by group A rotavirus (RVA), which is responsible for around half million mortality annually prior to vaccination. Relatively high rate of the morbidity and mortality highlights the necessity of applying preventive procedures particularly in developing countries. Two live attenuated RVA vaccines (Rotarix and RotaTeq) are licensed and now being used in many countries worldwide. Although these vaccines are shown to reduce the mortality up to 50%, several key questions yet remained to answer. Indeed, the licensed RV vaccines were found to be less effective in countries of sub‐Saharan Africa and Southeast Asia. Therefore, developing next generation RVA vaccines is warranted. VP6 is highly abundant and conserved protein that forms the middle layer of RV particles and was shown to be both antigenic and immunogenic. Although it does not induce neutralizing antibodies, different VP6 preparations were found to induce homologous and cross‐reactive immune responses with partial protection from RVA replication. Although the molecular mechanisms are not fully elucidated, VP6‐based RVA vaccine candidates are worthy of further consideration. This review aims to focus on different aspects of VP6 protein and its potentiality for an alternative RV vaccine against RV disease.

show abstract

Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity

Cited by 201 publications

References 173 publications

mRNA vaccines — a new era in vaccinology

mRNA vaccines — a new era in vaccinology

Epitope-based vaccine as a universal vaccination strategy against Toxoplasma gondii infection: A mini-review

Rotavirus VP6 as a potential vaccine candidate

Contact Info

Product

Resources

About